Wesbanco Bank Inc. Purchases Shares of 5,600 LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Wesbanco Bank Inc. bought a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,600 shares of the medical instruments supplier's stock, valued at approximately $470,000.

A number of other institutional investors have also recently made changes to their positions in the company. Barclays PLC boosted its stake in LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock valued at $3,396,000 after purchasing an additional 29,180 shares during the last quarter. Empowered Funds LLC purchased a new stake in shares of LeMaitre Vascular during the fourth quarter valued at $150,000. Shaker Investments LLC OH increased its holdings in LeMaitre Vascular by 0.8% in the 4th quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier's stock worth $1,285,000 after buying an additional 112 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in LeMaitre Vascular by 48.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier's stock worth $1,227,000 after buying an additional 4,330 shares during the last quarter. Finally, Legato Capital Management LLC lifted its stake in LeMaitre Vascular by 2.1% during the 4th quarter. Legato Capital Management LLC now owns 23,178 shares of the medical instruments supplier's stock valued at $2,136,000 after acquiring an additional 476 shares during the period. Hedge funds and other institutional investors own 84.64% of the company's stock.

Insider Activity

In other news, CEO George W. Lemaitre sold 18,733 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $84.77, for a total value of $1,587,996.41. Following the transaction, the chief executive officer now owns 1,873,651 shares of the company's stock, valued at approximately $158,829,395.27. The trade was a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 100,000 shares of company stock worth $8,556,857 over the last ninety days. Corporate insiders own 9.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on LMAT. Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Lake Street Capital boosted their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $97.83.

LeMaitre Vascular Stock Performance

Shares of LMAT stock traded down $0.24 during mid-day trading on Friday, reaching $81.13. 229,261 shares of the company's stock traded hands, compared to its average volume of 169,218. The firm has a market capitalization of $1.83 billion, a PE ratio of 44.33, a price-to-earnings-growth ratio of 2.22 and a beta of 0.83. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The firm has a 50 day moving average price of $83.86 and a two-hundred day moving average price of $90.29.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $59.87 million during the quarter, compared to analysts' expectations of $57.61 million. During the same quarter in the previous year, the company earned $0.44 EPS. The business's quarterly revenue was up 12.0% compared to the same quarter last year. As a group, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.99%. LeMaitre Vascular's dividend payout ratio is presently 40.40%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.